<<  Back

The Automation Partnership and MAIA SCIENTIFIC - a Harvard Bioscience Company - Announce Cello, a Fully Automated Cell Culture System

May 03,2004
The Automation Partnership and MAIA SCIENTIFIC - a Harvard Bioscience Company - Announce Cello, a Fully Automated Cell Culture System

ROYSTON, U.K. & GEEL, Belgium & HOLLISTON, Mass.--(BUSINESS WIRE)--May 3, 2004--The Automation Partnership (TAP) and MAIA SCIENTIFIC (formerly Union Biometrica NV - ESO, a wholly owned subsidiary of Harvard Bioscience - HBIO, NASDAQ) have completed a collaboration to incorporate the MAIA SCIENTIFIC microscopy reader technology into TAP's Cello™ automated cell culture system. As high-throughput screening has moved from molecular based tests to tests on living cells, cell culture has become a major bottleneck. Cello addresses this new bottleneck by completely automating the cell culture and clone selection process. Cello can culture multiple cell lines in parallel throughout all stages of their life cycle, from seeding through expansion and sub-cloning. This flexible, modular system provides the throughput and capacity needed to support several projects running in parallel with minimal operator involvement.

"Cello is an extremely robust solution, allowing for improved productivity wherever cells are grown in micro-well plates," said Tim Ward, Director of Cell Culture with The Automation Partnership.

"Cello will remove the bottleneck in the generation of new stable cell lines, enabling high throughput clone selections for pharmaceutical and biotech R&D. Being able to select the cell lines with exactly the right combination of characteristics, from many more cells, and take these through further rounds of selection and sub-cloning automatically, is one of Cello's key benefits" says Ward.

"In Cello, these functions must be integrated into the automatic operation of the system as a whole", said Natalie Carrick, Cell Culture Product Manager at The Automation Partnership. "At present, this type of measurement is either done manually, or by standalone imaging and analysis units which are manually loaded and operated. After a thorough market analysis, we chose MAIA SCIENTIFIC as our partner in developing the cell reader for the Cello platform. MAIA SCIENTIFIC was the only company able to provide the optimum combination of flexibility, system availability, and imaging and analysis quality to meet our demanding specifications. This includes not only the accuracy and consistency of the derived measurements, but also the reliability of the system components and the ability of the subsystem to detect, report, and recover from exceptions."

"Cello is a new paradigm for how hardware, software, chemistry and living biology can be integrated into a complete solution to a pressing need in pharmaceutical laboratories," said Johan Geysen, President of MAIA SCIENTIFIC. "The MAIA SCIENTIFIC microscopy reader and eaZYX™ software is effectively the eyes of the integrated system."

David Green, President of Harvard Bioscience, commented "We are very pleased with the partnership we have built with TAP - one of the world's leading suppliers of automation to the pharmaceutical industry - for the development of Cello. Partnership is an essential element in our three part growth strategy of innovation, acquisition and partnership. TAP's adoption of the MAIA SCIENTIFIC platform is another endorsement of the strength of the technology. We believe the future is very bright for integrated solutions like Cello, and for high-content screening using the MAIA SCIENTIFIC microscopy reader platform."

About The Automation Partnership. The Automation Partnership (TAP) is a world leader in the design, development and manufacture of advanced industrial automation solutions for the life sciences industry. TAP provides systems for automating and integrating processes for cell culture, sample management, screening and genomics applications. Over 100 TAP cell culture systems are installed at major pharmaceutical companies world-wide and these include Amgen, AstraZeneca, Aventis Pasteur, Avigen, Baxter Vaccines, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Novo Nordisk, Pfizer and Roche.

TAP, founded in 1988, is a private company with headquarters near Cambridge, UK and a U.S. sales and support office in Wilmington, Delaware. The Company, which employs over 180 staff, has profitable revenue of almost $40 million and continues to grow by developing and supplying successful market driven automation products.

About MAIA SCIENTIFIC. MAIA SCIENTIFIC, (previously known as Union Biometrica NV - ESO) a wholly owned subsidiary of Harvard Bioscience, develops, manufactures and markets novel instrumentation and applications for high-throughput / high information content screening. The MIAS-2™ microscopy readers and eaZYX™ imaging software offer unprecedented sensitivity, speed and flexibility, applicable across the drug discovery and development value chain. The MIAS-2™ and eaZYX™ platforms allow genomics, target validation, assay development, drug discovery and ADMET R&D programs to all be conducted on the same platform. Our assay expertise includes targets, cells, tissues, beads, bead labels and small animal organisms. For more information please visit www.maia-scientific.com.

About Harvard Bioscience. Harvard Bioscience (HBIO) is a global developer, manufacturer and marketer of innovative, enabling tools in drug discovery research at pharmaceutical and biotechnology companies, universities and government laboratories. HBIO sells its products to thousands of researchers in 100 countries through its direct sales force, its 1,100 page catalog, various specialty catalogs and through its manufacturing operations in the United States, the United Kingdom, Belgium, Austria and Germany and sales offices in France and Canada. For more information please visit www.harvardbioscience.com.

The statements made in this press release about Harvard Bioscience or any of its subsidiaries (the Company) that are not statements of historical fact are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include, but are not limited to, statements about the effect of new technologies on the drug discovery process, the financial and technological impact of collaborations on the Company and the Company's plans, objectives and intentions that are not historical facts.

Factors that may cause the Company's actual results, performance or achievements to differ materially from those in the forward-looking statements include, but are not limited to, the Company's failure to earn revenue under any collaboration agreement, to develop new technology, and the impact of other business strategies on the Company's financial condition, results of operations or stock price, as well as those factors set forth under the heading "Important Factors That May Affect Future Operating Results" in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2003, as well as other risks described in the Company's public filings or factors, if any, of which the Company is not currently aware. The Company may not update these forward-looking statements, even though its situation may change in the future, unless it has obligations under the Federal securities laws to update and disclose material developments related to previously disclosed information.

CONTACT: Harvard Bioscience, Inc.
David Green, 508-893-8999
dgreen@harvardbioscience.com

SOURCE: Harvard Bioscience, Inc.



Disclaimer:
The information contained within this and other Harvard Bioscience Web pages should be deemed accurate and current as of the date of the most recent update, or if no update information has been provided, the date of issuance. Harvard Bioscience assumes no responsibility for any misincurrances or misstatements which occur as the result of the reading of dated material. Users are strongly encouraged to check dates of issuance and most recent update of any information contained within, or linked to, Harvard Bioscience’s web site. For Harvard Bioscience’s most current information please reference Harvard Bioscience public filings with the Securities and Exchange Commission located at http://www.sec.gov.